Brought to you by 
Boston Scientific shells out $500mm up front for Augmenix
02 Sep 2020
Executive Summary
In its seventh acquisition this year, Boston Scientific Corp. is paying $500mm in cash to acquire closely held device maker Augmenix Inc. The transaction also includes up to $100mm in sales-based earn-outs.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
- Implantable Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boston Scientific shells out $500mm up front for Augmenix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice